Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Analyst Upgrade

Kodiak Sciences Inc. (NASDAQ:KOD)’s stock price gapped up prior to trading on Friday after UBS Group raised their price target on the stock from $50.00 to $80.00. The stock had previously closed at $39.76, but opened at $41.89. UBS Group currently has a buy rating on the stock. Kodiak Sciences shares last traded at $44.9810, with a volume of 1,727,148 shares changing hands.

A number of other equities analysts have also recently issued reports on KOD. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a research note on Friday. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.43.

Kodiak Sciences News Summary

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 GLOW2 results showed Zenkuda’s superiority vs. sham on the trial’s primary endpoint (large DRSS improvements), supporting the program’s previously reported GLOW1 success and paving the way toward a regulatory filing. PR Newswire: GLOW2 Topline Results
• Positive Sentiment: Mainstream press and market outlets are reporting the trial win and the stock rally, driving increased investor attention and heavy trading. Widespread coverage increases the likelihood of more short‑term inflows. Reuters: Shares Surge After Late‑Stage Success
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and raised its price target to $58 (from $38), implying significant upside vs. recent levels — a bullish analyst signal that can attract additional institutional interest. Benzinga: HC Wainwright Price‑Target Raise
• Neutral Sentiment: Industry press notes Kodiak expects to move toward a BLA/filing next after the twin Phase 3 successes — a clear path to commercialization but still subject to regulatory review and timelines. This is constructive long term but timing and approval risk remain. BioWorld: BLA Filing Next
• Negative Sentiment: Options activity showed an unusual surge in put buying (3,472 puts, a ~1,256% jump vs. typical daily put volume), suggesting some traders are hedging or betting on pullbacks amid the sharp rally.

Institutional Investors Weigh In On Kodiak Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Boone Capital Management LLC purchased a new position in shares of Kodiak Sciences during the third quarter valued at about $11,719,000. TD Asset Management Inc purchased a new stake in Kodiak Sciences in the third quarter worth about $992,000. Campbell & CO Investment Adviser LLC purchased a new stake in Kodiak Sciences in the third quarter worth about $488,000. Panagora Asset Management Inc. boosted its position in Kodiak Sciences by 28.5% during the 2nd quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company’s stock valued at $489,000 after acquiring an additional 29,113 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Kodiak Sciences by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 2,313,395 shares of the company’s stock worth $64,683,000 after acquiring an additional 363,103 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Trading Up 2.9%

The stock has a market cap of $2.17 billion, a PE ratio of -9.97 and a beta of 2.61. The business has a fifty day simple moving average of $24.95 and a two-hundred day simple moving average of $21.62.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.